2025-10-19 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data.  The report is structured with key figures first, followed by analysis and a final summary.

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 206.88%
*   **VOO Cumulative Return:** 97.05%
*   **Absolute Divergence:** 115.3
*   **Relative Divergence:** 52.8 (This means LLY's outperformance is in the 52.8th percentile of its historical range vs. VOO.)

**Analysis:** LLY has significantly outperformed the S&P 500, with a large absolute divergence in cumulative returns. The relative divergence indicates that while the outperformance is substantial, there's still room for it to grow further within its historical range.

#### Alpha, Beta Analysis

| Year      | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :---------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017 | 11.0%   | 76.1% | -17.0%  | -0.0   | 75.7  |
| 2016-2018 | 39.0%   | 68.9% | 24.0%   | -0.0   | 103.7 |
| 2017-2019 | 41.0%   | 68.9% | 19.0%   | 0.4    | 117.8 |
| 2018-2020 | 34.0%   | 79.8% | 10.0%   | 0.4    | 151.4 |
| 2019-2021 | 53.0%   | 79.8% | 7.0%    | 0.5    | 247.6 |
| 2020-2022 | 64.0%   | 79.8% | 65.0%   | 0.4    | 328.0 |
| 2021-2023 | 125.0%  | 78.9% | 124.0%  | 0.2    | 522.6 |
| 2022-2024 | 134.0%  | 81.2% | 113.0%  | 0.2    | 692.1 |
| 2023-2025 | 98.0%   | 83.5% | 37.0%   | 0.2    | 719.7 |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate has been very strong, especially in recent years (2021-2024).
*   **MDD:** Maximum Drawdown is significant, indicating periods of substantial price decline. Investors should be aware of LLY's high volatility.
*   **Alpha:**  Alpha is generally positive, and particularly high in recent periods, showing LLY's strong outperformance compared to its expected return based on market movements.
*   **Beta:** Beta is relatively low, suggesting that LLY is less sensitive to overall market movements than the S&P 500. This has decreased in recent years, which may be a sign of its business becoming more defensive.
*   **Market Cap:** Consistently increasing, indicating significant growth in the company's value.

### 2. Recent Stock Price Movements

*   **Current Price:** $802.83
*   **Previous Close:** $819.38
*   **Change:** -2.02%
*   **5-Day Moving Average:** $816.11
*   **20-Day Moving Average:** $796.91
*   **60-Day Moving Average:** $751.63

**Analysis:** The current price is below the 5-day moving average but above the 20-day and 60-day moving averages. The price decreased by 2.02% from the previous day, which can indicate a short-term downtrend.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment Recommendation)
*   **RSI:** 68.48 (Approaching overbought territory)
*   **PPO:** -0.33 (Slightly oversold)
*   **Hybrid Signal:** Sell 79.7% of holdings (Cash Ratio: 79%)
*   **Recent (20-day) Relative Divergence Change:** -3.5 (Short-term decline)
*   **Expected Return:** 120.4% (Long-term, vs. S&P 500)

**Analysis:** The MRI suggests a low investment recommendation. The RSI is nearing overbought levels, while the PPO is slightly oversold. The hybrid signal advises selling a significant portion of holdings. The recent decline in relative divergence further suggests a short-term downtrend. However, the expected return is extremely high, indicating a potentially strong long-term outlook. The price change from the previous close (-2.02%) reinforces the short-term downward pressure.

### 4. Recent News & Significant Events

*   **Analyst Report: Elanco Animal Health Incorporated:** (Irrelevant to LLY directly but reflects general market analysis)
*   **Stock Market Today: Indexes Up In Strong Week On Trump News; Oracle Dives:** (General market news)
*   **These Stocks Moved the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More:** (LLY experienced significant movement)
*   **Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive:** (Specifically impacts LLY due to its obesity drug pipeline)
*   **Pharma Stocks Fall After Trump Says Ozempic Could Be Much Cheaper:** (Broad sector pressure)
*   **Why Eli Lilly (LLY) Stock Is Down Today:** (Directly addresses the cause of the stock's recent decline)

**Analysis:** Recent news indicates that LLY's stock is facing downward pressure due to concerns about potential drug price cuts, particularly in the obesity drug market. This seems to be the primary driver of the recent price decrease.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 1.79)
*   **Target Price:** $891.00 (Avg) / $1190.00 (High) / $650.00 (Low)

**Analysis:** The analyst consensus is "Buy," with an average target price significantly higher than the current price. This suggests that analysts, on average, believe the stock is undervalued. However, the range of target prices is wide, indicating uncertainty.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
| :----------- | :----- | :------------- |
| 2025-08-07 | 6.30 | $15.56B       |
| 2025-05-01 | 3.07 | $12.73B       |
| 2024-10-30 | 1.08 | $11.44B       |
| 2024-08-08 | 3.29 | $11.30B       |
| 2025-08-07 | 3.29 | $11.30B       |

**Analysis:**  The most recent EPS (6.30) and revenue ($15.56B) show strong growth compared to previous quarters. This positive earnings trend is a good indicator.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| :------------- | :--------- | :-------------- |
| 2025-06-30 | $15.56B | 84.27%        |
| 2025-03-31 | $12.73B | 82.53%        |
| 2024-12-31 | $13.53B | 82.24%        |
| 2024-09-30 | $11.44B | 81.02%        |
| 2024-06-30 | $11.30B | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
| :------------- | :---------- | :-------- |
| 2025-06-30 | $18.27B   | 30.98%  |
| 2025-03-31 | $15.76B   | 17.50%  |
| 2024-12-31 | $14.19B   | 31.07%  |
| 2024-09-30 | $14.24B   | 6.81%   |
| 2024-06-30 | $13.56B   | 21.88%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been consistently increasing.  The Profit Margin is exceptionally high and stable, indicating strong operational efficiency and pricing power.
*   **Capital and Profitability:**  Equity is growing, and the Return on Equity (ROE) is strong, suggesting efficient use of shareholder capital.

### 7. Overall Summary

Eli Lilly (LLY) has demonstrated exceptional historical performance, significantly outperforming the S&P 500. Recent earnings and financial data indicate strong revenue growth, high profit margins, and efficient capital utilization. However, recent news regarding potential drug price cuts is causing short-term downward pressure on the stock. While technical indicators suggest caution (approaching overbought RSI, sell signal), the long-term expected return remains very high, and analyst consensus is still positive.

**Investment Recommendation:**

LLY presents a mixed picture. The long-term outlook is promising, driven by strong fundamentals and growth potential. However, the short-term faces uncertainty due to political and pricing pressures.

*   **Potential investors:** Should be aware of the short-term risks and consider a gradual entry strategy, taking advantage of potential dips.
*   **Current holders:** Might consider trimming some holdings, as suggested by the hybrid signal, but should maintain a core position for the long-term potential.
